Search the Newsreel

Tonix Pharmaceuticals Holding Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TNXP) 2026-08-14

Tonix Pharmaceuticals Holding Corp. (TNXP) has released its Q2 2026 earnings call presentation. The company reported an EPS of -$2.47, beating estimates by $0.15, and revenue of $13.54M, surpassing estimates by $5.82M with a 577.88% year-over-year increase. The slide deck provides details related to …

Eton Pharmaceuticals (ETON) Stock Reprices Higher After Profit Inflection

Eton Pharmaceuticals (ETON) stock surged 44.3% to US$58.86 after reporting a significant profit inflection in Q2 2026, with net income reaching US$11.6m and EPS of US$0.42 on US$37.6m revenue. This performance has led to increased revenue guidance for 2026 and supports the company's rare …

Intuitive Machines Inc (LUNR) Stock Up 8.3% but GF Value Says Ov

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements and concealed material adverse …

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential federal securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam significantly lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop …

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than …

What's Going On With Marimaca Copper Corp Stock Friday?

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. announced the granting of non-statutory stock options to two new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 14,600 shares of common stock, with an exercise price of $14.75 per share, …

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price …

Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate

Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju have reported significant beneficial ownership in Eloxx Pharmaceuticals (ELOX). Dr. Srinivas Akkaraju holds 9.99% of the common stock, while each Samsara BioCapital-affiliated entity owns 5.0%. This includes common shares and Pre-Funded Warrants subject to a …

Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively reported an 8.1% beneficial ownership stake in X4 Pharmaceuticals, Inc. This disclosure was made via an amended Schedule 13G filing, indicating shared voting and dispositive power over 8,085,006 shares, including …

Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts …

MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise

MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …

Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing (Form ARS) by Phio Pharmaceuticals Corp. (PHIO) on August 14, 2026. The filing has a low impact and neutral sentiment, and the document is available as a PDF. The article also provides recent news and other SEC …

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares

RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The …

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress

Citius Pharmaceuticals reported strong Q3 2026 financial results, including $7.1 million in commercial sales revenue for the first nine months of the fiscal year and $17 million in cash reserves. The company highlighted significant progress with its lead product, LYMPHIR, noting an 86% objective …

ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants

ADAR1 Capital Management, along with ADAR1 Capital Management GP, LLC and Daniel Schneeberger, have reported a beneficial ownership of 9.9% in Kiora Pharmaceuticals (KPRX). This stake, detailed in an amended passive investment disclosure (SCHEDULE 13G/A), includes common shares and shares underlying pre-funded and milestone …

Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in Kiora Pharmaceuticals, Inc. (KPRX) through a Schedule 13G/A filing. As of June 30, 2026, they beneficially own 491,889 shares, including those acquirable through convertible …

Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 9.91% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. (ELOX) through a Schedule 13G filing. As of June 30, 2026, the reporting persons beneficially own 400,000 shares, with shared voting and …

Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) stock fell 2.07% on Friday, closing at $505.75, amid a general market decline where the S&P 500 and Dow Jones Industrial Average also saw losses. This marked the third consecutive day of losses for the company's shares.

NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk

NRx Pharmaceuticals reported its Q2 2026 results, showing significant growth in net patient service revenue to $1.1 million for the quarter and $2.2 million for the first six months, primarily through its HOPE subsidiary's acquired Florida behavioral health clinics. Despite this new revenue stream …

Intuitive Machines (LUNR) Stock Could Trade At A Premium Despite Record Backlog

Lexicon Pharmaceuticals (LXRX) Completes Phase III Enrollment, Is The 38% Undervaluation Case Convincing?

LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have reported a beneficial ownership of 5.0% in LB Pharmaceuticals Inc. (LBRX), totaling 1,447,310 shares, through an amended Schedule 13G filing. This ownership percentage is based on 28,676,652 shares outstanding as …

Intuitive Machines Keeps $1B Revenue Goal as Contract Timing Shapes Outlook

Mamata Machinery Q1FY27 loss widens to ₹347 million on deferred execution

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND

Quoin Pharmaceuticals Ltd. (QNRX) reported a net loss of $5.37 million for the second quarter of 2026, an increase from $3.70 million in the prior year. Despite this, the company's cash position is expected to fund operations into 2027. The FDA also conditionally approved …

Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition

Mamata Machinery granted patent for pouch shuttle mechanism for 20 years

Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

Southpoint-related entities and individual John S. Clark have filed an amended Schedule 13G/A for Fennec Pharmaceuticals Inc. (FENC), indicating that they now beneficially own 0 Common Shares, representing 0% of the class. This filing signifies that their ownership is 5 percent or less, with …

Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026

Galmed Pharmaceuticals (GLMD) has announced a 1-for-8 reverse share split, consolidating its ordinary shares, with post-split trading expected to begin on August 19, 2026, on the Nasdaq Capital Market. This action will reduce the number of outstanding shares from 8,332,518 to approximately 1,041,565 and …

Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity

Amneal Pharmaceuticals director John Kiely reported selling 50,000 shares of Class A Common Stock at a weighted average price of $17.64 per share on August 13, 2026. Additionally, he made a charitable donation of 10,000 shares of Class A Common Stock to a donor-advised …

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing …